Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151001 | 1.00 | KCNH2 (0.45) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3603387 | 0.87 | KCNH2 (0.46) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3147101 | 0.86 | CYP3A4 (0.59) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3602142 | 0.86 | KCNH2 (0.44) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL5057969 | 0.86 | KCNH2 (0.43) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL13119805 | 0.85 | KCNH2 (0.48) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3159602 | 0.85 | CYP3A4 (0.49) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3151052 | 0.85 | CYP3A4 (0.55) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3152186 | 0.85 | CYP3A4 (0.44) | KCNH2CYP3A4CYP2D6CYP2C9SLC22A12 | |
| SCHEMBL5057955 | 0.84 | KCNH2 (0.44) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | KCNH2 3353/4885CYP3A4 64/4885CYP2D6 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.